home / stock / prds / prds news

PRDS News and Press, Pardes Biosciences Inc. From 02/03/22

Stock Information
Company Name: Pardes Biosciences Inc.
Stock Symbol: PRDS
Market: NASDAQ
Website: pardesbio.com
Menu
PRDS PRDS Quote PRDS Short PRDS News PRDS Articles PRDS Message Board
Get PRDS Alerts

News, Short Squeeze, Breakout and More Instantly...
PRDS - Pardes Biosciences Announces FDA Clearance of IND Application for PBI-0451, an Oral Antiviral Drug Candidate for the Treatment and Prevention of SARS-CoV-2 Infections

CARLSBAD, Calif., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associa...
PRDS - Palisade Bio, Pharming lead healthcare gainers; LogicBio Therapeutics, Pardes among losers

Gainers: Palisade Bio (NASDAQ:PALI) +23%. Pharming Group (NASDAQ:PHAR) +14%. Entasis Therapeutics (NASDAQ:ETTX) +13%. Epizyme (NASDAQ:EPZM) +11%. IceCure Medical (NASDAQ:ICCM) +10%. Losers: LogicBio Therapeutics (NASDAQ:LOGC) -50%. Pardes Bios...

PRDS - Pardes Biosciences to Present at J.P. Morgan Healthcare Conference

CARLSBAD, Calif., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage biopharmaceutical company developing PBI-0451 as a potential novel direct-acting, oral antiviral drug candidate for the treatment and prevention of SARS-CoV-2 infections and associa...

Previous 10 Next 10